Can-Fite BioPharma Ltd. (CANF)
NYSE American - Nasdaq Real Time Price. Currency in USD
Add to watchlist
At close: 03:59PM EST
| Previous Close | 0.8330 |
| Open | 0.8200 |
| Bid | 0.8210 x 1100 |
| Ask | 0.8400 x 1200 |
| Day's Range | 0.8210 - 0.8400 |
| 52 Week Range | 0.6900 - 2.6000 |
| Volume | |
| Avg. Volume | 68,784 |
| Market Cap | 23.287M |
| Beta (5Y Monthly) | 1.45 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.7500 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.00 |
- Business Wire
Can-Fite Reports Third Quarter 2022 Financial Results & Provides Clinical Update
PETACH TIKVA, Israel, November 25, 2022--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced financial results for the quarter ended September 30, 2022.
- Zacks
Catalyst's (CPRX) Q3 Earnings & Revenues Surpass Estimates
Catalyst's (CPRX) earnings and revenues beat estimates for the third quarter of 2022. The company increases the full-year revenue guidance.
- Zacks
Pacira's (PCRX) Q3 Earnings Miss Estimates, Revenues Beat
Pacira's (PCRX) earnings fall shy of estimates in the third quarter of 2022 while revenues beat the same.
© 2022 Yahoo. All rights reserved.
